Epizyme, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2007)

Organization Overview

First Clinical Trial
2012
NCT01684150
First Marketed Drug
2020
tazemetostat
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Epizyme, Inc. | EPIZYME INC